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A derivative of phencyclidine (PCP, 1 in fig. 1) bearing an isothiocyanate moiety on the meta position of 
the aromatic ring (Metaphit, 3 in fig. 1) has been synthesized and identified as a rapid and specific site- 
directed acylating agent of the [3H]phencyclidine binding site in rat brain homogenates. The percentage of 
sites irreversibly inactivated by Metaphit was found to be the same in the hippocampus and striatum and 
the remaining sites were unaffected by Metaphit treatment under any conditions, suggesting that at least 
two distinct binding sites are present. An isomeric isothiocyanate derivative did not irreversibly inhibit 
[3H]phencyclidine receptors, indicating structural specificity for Metaphit in the inhibition of these recep- 
tors. The availability of Metaphit should greatly facilitate study of the structure and function of the phen- 
cyclidine receptors. 
Phencyclidine (PCP) Metaphit 1-[1-(3-Isothiocyanatophenyl)cyclohexyl]piperidine 
Phencyclidine receptor affinity ligand Phencyclidine receptor Irreversible inhibitor 
1. INTRODUCTION 
The illicit use of phencyclidine (PCP, 1 in fig.1) 
is a major problem in the USA that has rivaled the 
abuse of heroin and cocaine. The bizarre 
dissociative behavioral effects produced in humans 
by PCP range from schizophrenia-like states to 
violently aggressive behavior and self-mutilation. 
These effects have stimulated interest in the 
biochemical pharmacology of PCP and recent 
studies have described stereoselective, saturable 
binding sites in rat brain [l-3] and other species 
141. Despite some initial controversy concerning 
the pharmacological relevance of the site, a high 
degree of correlation between binding affinity and 
in vivo activity of several PCP-mimetics support 
the contention that the site is indeed a phar- 
macological receptor ([ 1,2] and unpublished). The 
recent finding of an endogenous peptide with a 
binding affinity much greater than PCP for this 
* To whom reprint requests should be addressed 
site [.5] raises questions concerning the 
physiological function of these sites in the CNS, 
and their possible involvement in neuropsychiatric 
states. 
Recent efforts in our laboratory have resulted in 
the synthesis of compounds which specifically 
acylate mu and delta opioid receptor subtypes 
[6-91. In view of the proposed relation between the 
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Fig.1. Structure of PCP (l), m-amino-PCP (2), and 
Metaphit (3). 
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[3H]PCP binding site and the putative sigma opiate PCP (final concentration lO_&L for nonspecific 
receptor [lO,l l], we have synthesized PCP binding). The total number of counts bound with 
derivatives bearing acylating functional groups in 8 nM f3H]PCP was about 12000 cpm and the 
an attempt to develop an affinity label for this number of nonspecific counts was about 
recognition site which could prove to be of value in 3000 cpm. The mixture was incubated for 60 min 
probing its role in the CNS, and possibly aid in at 5”C, and filtered through Whatman GF-B filters 
isolation and characterization of the binding site that had been soaked in 0.03~0 poly-L-lysine 
proteins. We now report synthesis and biochemical (Sigma, 1%4~ 150~-3~~) for 2 h at 5°C. Filtra- 
characterization of the first el~ctrophilic acylating tions were performed on a Brandell Cell Harvester. 
PCP derivative l-[ l-(3-isothiocyanatophenyl)cyc- The filters were washed with two 5-ml aliquots of 
lohexyllpiperidine, which we have termed ‘Me- ice-cold fresh buffer, and transferred to counting 
taphit’ (3 in fig.1). viafs. Hydro~uor scintillation cocktail (National 
2. MATERIALS AND METHGDS 
Metaphit (3) was prepared from the known (121 
PCP analogue 2 (in fig.1) using standard pro- 
cedures 19,131 and was fully characterized by spec- 
tral data and combustion analysis. The 
hydrochIoride salt was prepared in isopropanol 
and recrystallized from methanol-ether, m.p. 
214-216°C. 
2.2. Receptor b~~~~~g assays 
Binding experiments were conducted with adult 
male Sprague-Dawley rats (Taconic Farms, Ger- 
mantown, NY), which were decapitated and the 
brains quickly removed and dissected on ice. Hip- 
pocampus and striatum were separated and im- 
mediatety homogenized in 70 vols ice cold 
Tris-HCI (5 mM, pH 7.4), or quick-frozen on dry 
ice for later use. For homogenization, a Brinkman 
Polytron (setting 6) was employed for a period of 
20 s. The homogenates were centrifuged at 20~ 
x g for 20 min at 5”C, and the pellet resuspended 
in fresh buffer; this washing procedure was 
repeated a total of three times. The final washed 
pellet was suspended in 3.5 vols fresh buffer and 
kept on ice prior to the experiment. Homogenates 
were treated with I-lO/rM Metaphit at 0°C for 
varying time periods, foIlowed by three additional 
consecutive washings to remove unreacted 
Metaphit. The binding assay procedure was 
adapted from Zukin et al. 114). lncubatjons were 
performed in a total volume of 1 ml consisting of 
0.9 ml tissue homogenate (containin 0.7-1.0 mg 
protein), 0.05 ml of 8 nM [3H]PCP (48 Ci/mmol, 
New England Nuclear), and 0.05 ml of buffer or 
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Fig.2, Effect of Metaphit treatment on [3kI]PCP binding 
to rat brain homogenates. Results shown are composite 
plots of 5 separate xperiments. (A) Displacement curve 
for PCP using control (washed, untreated) tissue. (B) 
Displacement curve on a portion of the same tissue 
which had been pretreated with 10,~M Metaphit. 
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Diagnostics) was added, and the vials allowed to 
stand overnight prior to counting. All assays were 
performed in triplicate. Data from these ex- 
periments were analyzed using the LIGAND pro- 
gram [15]. Binding methodologies for other recep- 
tors were taken from the literature [16-191. 
3. RESULTS 
Comparison of displacement curves generated 
with untreated control tissue (fig.2A) and tissue 
treated with 10pM Metaphit (fig.2B) revealed a 
significant loss of binding capacity in the treated 
tissue. Scatchard plots of the data (fig.3) clearly 
show that Metaphit treatment results in a signifi- 
cant loss of sites without altering the affinity of the 
remaining sites (& for control, 1.14 x low7 M, for 
treated 1.17 x lo-’ M; B,,, for control, 
2.96 pmol/mg protein, for treated, 1.09 pmol/mg 
protein). In control experiments, substitution of 
Metaphit with PCP at various concentrations 
(IO-50 FM) did not result in a significant loss of 
tissue binding, indicating that the washing pro- 
cedure used was sufficient to remove any unbound 
ligand from the tissue. The percentage of binding 
sites which were acylated by Metaphit treatment 
did not differ in the hippocampus and striatum. 
Tissue homogenates prepared from rat hippocam- 
0.03 
r 
Bound (pmole/mg protein) 
Fig.3. Scatchard plots of the data shown in fig.ZA,B. 
Control, 0; treated, O. 
pus showed 45% acylation after exposure to 10 PM 
Metaphit, and 50% of the sites in homogenates 
from striatum were Metaphit sensitive (table 1). In 
all cases a significant component of control 
[‘H]PCP binding sites remained intact following 
treatment with Metaphit, and no conditions were 
found for complete acylation of these remaining 
sites. These results suggest hat the L3H]PCP bind- 
ing site population consists of at least two subtypes 
which can be differentiated on the basis of their 
sensitivity to Metaphit. Variation of treatment 
time revealed that a 5 min exposure was sufficient 
to label all susceptible sites, and longer treatments 
of up to 2 h did not resuh in any additional loss of 
binding (fig.4). Interestingly, the Metaphit isomer 
1 -( 1 -phenyl)cyclohexyl-4-isothiocyanatopiperidine 
(with an isothiocyanate function on the piperidine 
ring rather than on the aromatic ring) did not ir- 
reversibly inhibit [3H]phencyclidine receptors 
under the usual conditions, indicating Metaphit 
structural specificity for the acylation of these 
receptors. The binding affinity of this Metaphit 
Table 1 
Ability of 1OpM Metaphit to reversibiy and irreversibly 
antagonize binding of various brain receptor hgands 
Ligand Maximum ICSO ~,uM) ICSO (uM) 
% acylation for for 
by IO/M Metaphit PCP 
Metaphit 
i3H]PCP 
Hippocampus 
Striatum 
i3HlQNB 
[3H]Dihydro- 
4Sb 0.075 
50b 0.070 
0 19 25 
morphine 0 11 13a 
13H]Diazepam 0 > IO00 >200 
a Obtained from [ 181 
b These average numbers are not statistically different 
The ligand concentrations used were: 8 nM [3H]phen- 
cyclidine, 0.5 nM t3H]QNB, 1 nM [3H]dihydromor- 
phine, and 5 nM ~3H]diazepam. The binding methodo- 
logy for PCP [14] was modified (figs 2A,B,3,4), the 
others were from the literature [16-191. Acylation by 
Metaphit refers to the % of acylation in washed, treated 
tissue compared with similarly washed controls. ICso 
values for Metaphit were estimated from competitive 
displacement curves 
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Fig.4. Time course of Metaphit acylation, plotting % of 
control sites remaining after 10 FM Metaphit 
pretreatment vs pretreatment ime. 
isomer was between two and three orders of 
magnitude less than PCP. 
4. DISCUSSION 
The extreme reactivity of Metaphit toward a 
subpopulation of sites was demonstrated by the re- 
quirement for high concentrations of added PCP 
to protect these sites. Only when the tissue 
homogenate (pooled striatum and hippocampus) 
was preincubated with 50 PM cold PCP prior to a 
brief (10 min) exposure to Metaphit (IO/M, S’C) 
was an attenuation observed in the number of sites 
acylated (25% decrease in sites, compared with a 
49% loss when PCP was not included as a pretreat- 
ment). The results suggest hat susceptible binding 
sites may contain a suitably located lysine or cys- 
teine residue, since isothiocyanates are particularly 
reactive toward amine and sulfhydryl nucleophiles 
[9,20]. The reactivity of the isothiocyanate moiety 
was also a concern with respect o solution stabili- 
ty, since the Tris-HCl buffer used contains a 
primary amino group. The stability of Metaphit in 
Tris buffer was established experimentally, as was 
its rapid reaction with methylamine under the same 
conditions. The UV spectrum of Metaphit taken in 
methanol or water showed absorption maxima at 
269 and 278 nm. Comparison of UV spectra taken 
at zero time and after 2 h at room temperature, of 
a 10pM solution of Metaphit in 5 mM Tris-HCl 
(pH 7.4) revealed no change in the spectrum, and 
only small changes were observed after 16 h at 
room temperature, which could be accounted for 
by approx. 15% hydrolysis in that time. The 
failure to observe reactivity between the primary 
amino group in Tris and Metaphit is probably due 
to the steric hindrance of the amino group in Tris 
and hydrogen bonding of this function to the 
hydroxyl groups. Addition of excess methylamine 
to a Metaphit solution resulted in the rapid disap- 
pearance of these bands, coincident with the ap- 
pearance of a new absorption at 241 nm. This lat- 
ter band was attributed to the thiourea derivative 
of Metaphit produced by reaction with the 
methylamine. Thus, any reaction with the Tris 
component of the buffer would be negligible in the 
brief tissue exposure time employed. 
The acylating specificity of Metaphit for the 
[3H]PCP site was determined because PCP and its 
congeners have been reported to interact at 
cholinergic receptors [18] and with opioid recep- 
tors, and possess analgesic activity [19]. Metaphit 
was found to displace [3H]QNB (quinuclidinyl 
benzilate) from muscarinic receptors in rat brain 
homogenates with a potency equivalent to PCP, 
without a significant loss of QNB binding com- 
pared with control tissues (table 1). Likewise, 
Metaphit competitively inhibited [3H]dihydromor- 
phine binding, but no irreversible blockade of 
opioid receptors could be observed. Metaphit was 
inactive in all respects toward the [3H]diazepam 
site. These data, coupled with the insensitivity of a 
portion of the [3H]PCP binding sites, indicate that 
Metaphit is highly specific as a covalent labelling 
reagent. 
In summary, the PCP congener Metaphit has 
been found to covalently modify a significant por- 
tion of the [3H]PCP binding sites found in rat 
brain. The insensitivity of some of these sites to 
acylation leaves open the possibility that the bind- 
ing site pool is comprised of at least two different 
sites, perhaps with different pharmacological 
roles. Biochemical and pharmacological studies 
addressing this question and others concerning the 
structure and function of phencyclidine recogni- 
tion sites are in progress using Metaphit and con- 
geners. Metaphit has been noted to antagonize 
PCP receptor binding and behavioral actions in 
the rat after icv introduction (unpublished). 
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